Business
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful
About this update from Viatris Inc.
[{"type":"text","content":"Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxicam and Low-Dose Estrogen Weekly Patch in the U.S., and Pitolisant and Effexor® for GAD in JapanUnlocking Long-Term Value Through Potential Blockbusters Selatogrel and Cenerimod Strong Cash Flow Generation Enabling Capital Return and Disciplined Business DevelopmentProviding Long-Term Targets for Sustained Growth Through 2030 PITTSBURGH, March 19, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030.Executive Commentary\"Over the past several years, we have taken decisive actions to strengthen the foundation of Viatris by simplifying the portfolio, strengthening the balance sheet and stabilizing the base business,\" said Scott A. Smith, CEO, Viatris. \"Today, we are entering the next phase of our evolution. With a growing base business, multiple anticipated near-term launches, a promising innovative pipeline and the financial flexibility to pursue disciplined accretive business development, we believe Viatris is well positioned to deliver sustained revenue and earnings growth through the end of the decade while continuing to create value for patients and shareholders.\"\"Our diversified portfolio and strong cash flow generation provide significant financial flexibility to invest in growth while maintaining a disciplined capital allocation framework,\" said Doretta Mistras, CFO, Viatris. \"We expect to have more than $11 billion in cash available for deployment through 2030, which would enable us to return capital to shareholders and pursue accretive business development to further strengthen our long-term growth profile.\"Key Elements to be Highlighted at the Investor EventDuring the event, the Company will highlight key elements supporting its long-term growth targets, including its:Strategic vision and prioritiesR&D capabilities and pipeline overviewCommercial capabilities and building blocks of growthPortfolio strategy and business developmentFinancial framework for accelerating shareholder valueThe Comp...